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Thyroid hormone- (TR) and Liver X- (LXR) 
receptors are transcription factors involved 
in lipogenesis. Both receptors recognize the 
same consensus DNA response element in 
vitro. It was previously shown that their 
signalling pathways interact in the control of 
cholesterol elimination in the liver. In the 
present study ChREBP, a major 
transcription factor controlling the 
activation of glucose-induced lipogenesis in 
liver, is characterized as a direct target of 
thyroid hormones (TH) in liver and white 
adipose tissue (WAT), the two main lipogenic 
tissues in mice. Using genetic and molecular 
approaches ChREBP is shown to be 
specifically regulated by TR but not by 
TR in vivo even in WAT where both TR 
isoforms are expressed. However this isotype 
specificity is not found in vitro. This TR 
specific regulation correlates with the loss of 
TH-induced lipogenesis in TR-/- mice. 
Fasting/refeeding experiments show that 
TR is not required for the activation of 
ChREBP expression particularly marked in 
WAT following refeeding. However TH can 
stimulate ChREBP expression in WAT even 
under fasting conditions suggesting 
completely independent pathways. Since 
ChREBP has been described as an LXR 
target, the interaction of LXR and TR in 
ChREBP regulation was assayed both in 
vitro and in vivo. Each receptor recognizes a 
different response element on the ChREBP 
promoter, located only eight base pairs 
apart. There is a crosstalk between LXR and 
TR signalling on the ChREBP promoter in 
liver but not in WAT where LXR does not 
regulate ChREBP expression. The molecular 
basis for this crosstalk has been determined 
in in vitro systems. 
De novo lipogenesis allows the synthesis of 
new molecules of fatty acids (FA) from acetyl 
CoA. High glucose and insulin concentrations 
induce this process converting the excess 
energy into triglycerides (TG), a more relevant 
molecule for storage purposes. In rodents both 
liver and WAT are efficient sites for 
lipogenesis. The synergic actions of insulin and 
glucose on the expression of lipogenic genes 
are mediated by key transcription factors. 
Insulin acts mainly through SREBP (Sterol 
Regulatory Element Binding Protein)-1c (1) 
while ChREBP (Carbohydrate Response 
Element Binding Protein) is the master factor 
for glucose-induced lipogenesis (2). ChREBP 
physiological function has mainly been studied 
in the liver. ChREBP
-/-
 mice display a 
diminution in both basal and glucose-induced 
liver FA synthesis, due to the decreased 
expression of ChREBP glycolytic and lipogenic 
targets (3). Most interestingly the ChREBP
-/-
 
mutation protects Ob/Ob mice from obesity and 
reduces their plasma glucose level (4) 
suggesting that inhibition of ChREBP might be 
of pharmacological interest to treat the 
metabolic syndrome. ChREBP is expressed in 
many other tissues including WAT where its 
possible lipogenic role is presently unclear. 
ChREBP activity is mainly regulated by post-
translational modifications that control its 
relocation to the nucleus and its DNA binding 
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activity (5). When active, ChREBP turns on the 
expression of genes harboring a ChoRE 
(Carbohydrate Response Element) in their 
promoters. All the genes encoding the enzymes 
involved in lipogenesis (FAS, ACC, SCD1, L-
PK, G6PD, ME, Spot14) are direct ChREBP 
targets. During fasting, ChREBP is inactivated 
and located in the cytoplasm. In contrast 
ChREBP mRNA level varies in a narrow range. 
In liver its level doubles when animals are 
switched from a fasted to a fed state (6). A 
similar up-regulation of its expression can be 
observed in mouse and human hepatocytes 
exposed to a high glucose concentration (7). In 
3T3L1 cells  insulin, glucose, and FA regulate 
ChREBP expression (8). In contrast to liver, 
ChREBP mRNA is very efficiently induced (10 
fold) following refeeding in WAT (6,8). The 
physiological consequence of this regulation in 
WAT remains unknown. 
Thyroid hormones (TH) up-regulate lipogenesis 
in liver but their roles in WAT are controversial 
(9-11). Their actions are mediated by the TR 
and TR nuclear receptors, which act as 
transcription factors by binding to specific TH 
response elements (TRE), as homodimers or 
heterodimers with the nuclear receptor RXR 
(12). Several genes involved in lipogenesis such 
as FAS, ACC, Spot14 or ME are positively 
regulated by TH in liver (13, 14). TRE have 
been identified in some but not all of their 
promoters. The expression pattern of TR and 
TR are only partially overlapping (15). In liver 
TR represents 80% of the TH-bound TR (16), 
whereas in WAT both receptors are highly 
expressed. The phenotyping of different TRKO 
mice shed light on the role of each isotype in 
mediating TH signal (17, 12). Importantly, in 
the organs where they are co-expressed, their 
function is not necessarily redundant. Recently 
two genes were described to be specifically 
regulated by either TR1 or TR18in the 
outer hair of the developing cochlea suggesting 
that each receptor might regulate its own set of 
targets in response to TH. The lipogenic effect 
of TH has been attributed to TR because in the 
liver TH regulation of FAS, ACC, Spot14 and 
ME is lost in TR-/- mice (13). However since 
TR is weakly expressed in this tissue, liver 
might not be the most appropriate tissue to 
assay isotype specificity. The LXR nuclear 
receptors could be involved in the lipogenic 
action of TR. Different levels of potential cross-
talk between LXRs and TR have indeed been 
described (19). For instance LXR expression 
has been described to be regulated by TH in 
mouse liver (20). At a functional level LXRs 
and TR regulate a common set of events 
especially in the liver where both receptors 
stimulate lipogenesis and cholesterol disposal. 
From a molecular point of view, these receptors 
can bind to identical (DR4) elements in vitro, 
although only one of these elements (in the 
cyp7a1 gene promoter) has been characterized 
as a common LXRs and TR response element 
(21). Interestingly, LXRs were recently shown 
to directly control ChREBP expression by 
binding to a DR4 element in its promoter (22). 
Another DR4 element located in the near 
vicinity was shown to mediate the positive 
effect of TH on ChREBP expression in the 
mouse liver (23).  
In this paper we show that TH directly activate 
ChREBP not only in liver (23), but also, to a 
higher extent, in WAT. In vivo this effect is 
TR but not TR dependent although both 
TR isoforms are strongly expressed in WAT 
whereas in vitro both isoforms can drive the 
expression of a reporter gene downstream of the 
ChREBP promoter and bind to the same 
response element. Despite its capacity to up-
regulate ChREBP expression TR is not 
required for ChREBP induction in response to 
the fasting/refeeding protocol. TR acts 
independently of LXR. Finally although ligands 
for these receptors could co-regulate the 
ChREBP promoter in liver, different 
approaches point out to a mutually exclusive 
binding of LXR and TR to this promoter.  
 
EXPERIMENTAL PROCEDURES 
 
Plasmids: The expression plasmids were all 
pSG5 based vectors (mouse TR, rat TR1, 
mouse RXRmouse LXR). The different 
promoters were cloned in the pGL3 basic vector 
and or PGL4.70[hRluc] (Promega, Charbon-
nières, France). The 3kbp upstream of the 
mouse ChREBP transcription start site were 
amplified by PCR using the primers 
ChREBPprom, cloned in pGL3basic/PGL4-
70(pChREBP). The mutants (pM1, pM2 and 
pM1M2) were obtained using site directed PCR 
mutagenesis (with M1 and M2 primer pairs). 
All plasmids were sequenced (Cogenics ge-
nome express, Meylan, France). 
Chemicals:Tri-iodothyronine (T3), Thyroxine 
(T4) were from Sigma-Aldrich (l’Isle D’Abeau, 
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France), the synthetic LXR ligand 
T0901317(T09) from Cayman Chemical 
(Montigny le Bretonneux, France). 
Animals and preparation of tissue samples: 
knock-out mice were in a C57black6:129sv 
mixed background. TR-/-, TR0/0 (17, 24, 25), 
LXRKO (26) and controls were previously 
described, fed ad libitum A04 diet (SAFE) and 
housed under recommended conditions. 3 to 5 
month old male mice were used unless indi-
cated otherwise. TH deficiency in adult animals 
was induced as described with a PTU 
containing diet (Harlan Teklad TD95125, 
Madison, WI) and followed or not by TH (mix 
of T4 and T3) injection (13). T09 was given by 
oral gavage once a day for three days (10mg/kg 
T09 in 100µl of methyl cellulose 1%). 
Pax8
-/-
 mice, which are genetically hypothyroid, 
were described to die before weaning (27), 
however some spontaneously survive. These 
rare survivors were used for experiments. 
For the fasting/refeeding protocol, mice fed a 
regular chow diet were fasted for 24h and either 
refed a 70% high carbohydrate diet (Harlan 
Teklad TD98090) or kept on fasting for an ad-
ditional 16h. 
Tissues were dissected immediately after cer-
vical dislocation, and flash frozen in liquid ni-
trogen. For WAT ex vivo culture, peri-testicular 
fat pads were dissected and cultured non dilace-
rated in 10% Charcoal stripped fetal bovine 
serum (FBS), 5ng/ml insulin complemented 
DMEM (Invitrogen, Cergy-Pontoise, France) 
for 24h before addition of ligands. All animal 
experiments were performed under Animal care 
procedures and conducted in accordance with 
the guidelines set by the European Community 
Council Directives (86/609/EEC).  
RNA extraction and expression analyses by 
relative quantitative RT-PCR (QRTPCR): 
RNAs were extracted using Trizol (Invitrogen). 
Total RNA was converted to cDNA using Su-
perScript II retrotranscription kit (Invitrogen). 
QRTPCR were performed using the Quantitect 
Syber green PCR kit (Qiagen, Courtaboeuf, 
France) on a Stratagene machine MX3000 pro 
(Stratagene, La Jolla, CA). Duplicates were run 
for each sample. The results were analyzed 
according to the CT method (28). 36B4 was 
always used as the reference gene, and the con-
trol group is either the non treated cells or the 
WT non injected animals unless otherwise indi-
cated. 
Cell culture and transient transfection assays: 
Hela (ATCC-CCL2) and 3T3-L1 (ATCC-CL-
173) cells were maintained in DMEM 
supplemented with 10% FBS (Invitrogen). For 
3T3-L1, cells were induced to differentiate 
using IBMX (insulin-dexamethasone-
Rosiglitazone) mix. To observe a better 
response to T3 cells were switched to DMEM 
medium supplemented with 10% charcoal 
stripped FBS before the experiments. T3 was 
used at 10
-8
M and T09 at 10-5M. Cells were 
harvested 24h (ChIP or WAT explants) or 36h 
(transient transfection assay) after ligand 
exposure. For transient transfections, Hela cells 
were seeded in 24-well plates and transfected 
with ExGen (Euromedex, Souffelweyersheim, 
France) following the manufacturer’s recom-
mendations and 0.5µg final DNA. pSG5 was 
added as a carrier when needed. Transfection 
efficiency was normalized using -Gal activity 
brought by cotransfection of CMV -Gal vec-
tor. For each experiment triplicate of each 
conditions were done, and each experiment 
have been repeated at least three times giving 
similar results. Only one experiment is shown 
and each point represents the average for the 
triplicate, the error bar is their standard 
deviation (SD).   
Chromatin Immuno-precipitation assays: The 
anti-TR antibody was raised against a C-
terminal peptide and affinity
 
purified with the 
same peptide, the anti-TR(TR-J52) and 
control IgG (normal mouse IgG) antibodies 
were purchased from Santa-Cruz, the anti 
RNA-polII (CTD4H8) from Upstate. Cells were 
cross-linked with 1% formaldehyde before lysis 
(in 1% SDS, 10mM EDTA, 50mM Tris-HCL 
pH 8.1) and sonication (200-700 bp DNA 
fragments). Lysates were diluted and pre-
cleared with herring sperm DNA (2µg/ml), 
BSA (2µg/ml), mouse IgG and protein G-
sepharose (GE Healthcare, Saint-Cyr au Mont 
d’or, France). Lysates were incubated with the 
cognate specific antibodies or IgG and protein 
G-sepharose. Beads were washed and eluted. 
Cross-link was reversed by overnight 
incubation at 65°C in the presence of RNAse A 
and 200mM NaCl. Samples were purified 
(Quiagen) and analyzed by Q PCR using the 
primer pairs NS1, NS2 and S1. 
EMSA: mTRα1, mTRß, mLXR and mRXR 
were in vitro translated (TNT kit Promega). The 
different single-strand oligonucleotides (F) 
were 
[γ-32P]
ATP labelled with T4 polynucleotide
 
kinase (Fermentas, Burlington, Ontario) before 
annealing
 
with their unlabelled antisens (R). 
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Probes were
 
purified and counted. 20000 cpm 
were used for each binding reaction. Unlabelled 
specific and nonspecific competitor probes 
were included at the indicated molar excess.  
Hepatic lipogenesis: Mice were given an IP 
injection of deuterated water (10ml/kg in 0.9% 
NaCl isotonic water) followed by 
administration of drinking water enriched with 
deuterated water (3% V/V) ad libitum for 24 h. 
Plasma was then collected for the measurement 
of deuterium enrichment in plasma water and in 
the palmitate of plasma TG as previously 
described (29). These enrichments were then 
used to calculate the contribution, expressed as 
per cent, of hepatic lipogenesis to the plasma 
TG pool (30).  
All the primer sequences are listed in SI1. 
Statistics: For mice experiments, the data 
presented represent the average values for the 
different animals (4 or 5) from the same 
genotype given the same treatment. The error 
bars represent SEM. Statistical relevance was 
determined using the one variable Anova 
method. 
 
RESULTS 
 
ChREBP expression is regulated by TH in the 
different lipogenic tissues in a TRdependent 
manner.  
ChREBP expression was recently shown to be 
regulated by TH in the liver of C57/BL6 mice 
treated with PTU/MMI treatment (23). Here the 
regulation of ChREBP was studied in the pax8 
(deprived of thyroid) mutant mice and Sv129 
mice treated with PTU (Figure 1-A). In both 
models TH injection induced ChREBP mRNA 
level in WAT and to a lesser extent in liver. 
Consistently the expression of FAS (a target of 
both TRs and ChREBP) and L-PK (a ChREBP-
only target gene) were also enhanced by TH, 
suggesting that ChREBP activity (and not only 
expression) is also up-modulated by TH. The 
TH-induced regulation of ChREBP was lost in 
TR-/- but not TR0/0 mice indicating that TR 
was required at least in the two metabolic 
tissues studied (Figure 1-B) despite the strong 
expression of TR in WAT. The critical role of 
TR for TH-induced hepatic lipogenesis was 
demonstrated in vivo using wild-type (WT) and 
TR-/- PTU-treated male mice. Whereas TH 
efficiently increased lipogenesis in WT (Figure 
1-C) the response was blunted in TR-/- mice. 
WAT lipogenesis was not measured due to 
technical limitations. 
TH/TR and nutritional status: two independent 
ways to regulate ChREBP expression. 
To determine the involvement of TH signalling 
in the physiological regulation of ChREBP 
expression, RNA level was assessed in liver 
and WAT in response to a fasting/refeeding 
protocol in both WT and TR-/- mice (Figure 2-
A). In agreement with published data, ChREBP 
RNA was found only up-regulated two fold in 
the liver (6). In contrast a dramatic increase of 
its expression was observed in WAT upon 
refeeding. This response was also observed in 
TR-/- mice indicating that TR is not required 
for this physiological process. We next 
determined whether ChREBP expression could 
be TH-regulated under all nutritional 
conditions. ChREBP, as well as FAS and 
Spot14 mRNAs, were induced by TH in the 
fasted (non lipogenic) conditions in WAT 
(Figure 2-B). In contrast TH failed to 
significantly activate these genes when mice 
were refed. This might be due to an already 
high ChREBP expression under these 
conditions. In the liver the extent of ChREBP 
mRNA regulation is much more limited and in 
contrast to WAT, the nutrition signal is 
dominant, blocking a potential effect of TH on 
the three target genes in the fasted state. 
TR binds to and activates ChREBP promoter 
via the previously described LXRE2. 
The results presented above identified TR/TH 
as a new way to modulate ChREBP expression 
in vivo. The mechanisms responsible for this 
regulation were then investigated in vitro. In 
contrast to what was observed in vivo TR but 
also TR, when co-expressed with RXR, were 
able to activate the 3.2 kbp ChREBP proximal 
promoter (figure 3-A), in the presence of TH 
(Figure 3-B). LXRdescribed to activate this 
same portion of the promoter (22) was used as a 
positive control. Two DR4 elements (LXRE1 
and LXRE2) were described in the mouse 
ChREBP promoter, LXRE1 being involved for 
LXR response (22), LXRE2 necessary for TH 
response (23). These binding specificities were 
confirmed here by the EMSA data (figure 3-C). 
All three receptors bound to a 44bp probe 
encompassing the two LXREs. However LXR 
binding was competed only by a LXRE1WT 
but not mutated probe whereas TR1 or 
TRbinding were only competed by a LXRE2 
WT but not mutated probe. The dependence on 
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these sites for transcriptional responsiveness to 
either TR or LXR was less obvious in 
transfection assay (Figure 3-B). The double 
M1M2 mutant still showed responsiveness to 
both compounds. This apparent discrepancy to 
EMSA results and published data for TR (23) is 
likely due to the inability of the four point mu-
tations introduced in each promoter construct to 
efficiently prevent TR binding. For LXR Cha et 
al actually also observed a residual induction of 
similar pM1 and pM1M2 constructs by the 
LXR agonist T09 (22). This suggests either that 
beside LXRE1, some other region(s) of the 
promoter could mediate the response to LXR or 
that like for TR the mutations introduced in 
LXRE1 are not disruptive enough. 
ChIP experiments were performed to investi-
gate the molecular mechanisms underlying the 
TR isoform specificity in the regulation of the 
endogenous ChREBP promoter. Differentiated 
3T3L1 adipocytes in which ChREBP mRNA is 
also induced by TH, were used. Similar to 
WAT these cells express both TR and TR 
(31). Both TRs were detected on the region 
containing the LXREs but not on upstream or 
downstream promoter regions. TR binding was 
independent of T3 in agreement with the 
accepted model for TR action. In contrast RNA 
polII was enriched at the transcriptional start 
site only in the presence of T3 (Figure 3-D). 
Altogether these data clearly demonstrate that 
both TRand TR bind to the LXRE2 in the 
ChREBP promoter and allow its induction in 
the presence of T3 at least in a reporter system. 
Crosstalk between TR and LXR signalling for 
the regulation of ChREBP expression. 
Published work described the LXR gene as a 
TH target in mouse liver (20). In the present 
study no significant regulation of LXR 
expression by TH or T3 was detected in the 
different models and experiments performed 
(Figure 4 A and D). Furthermore TH was 
capable of activating the expression of 
ChREBP as well as other lipogenic genes in 
liver of PTU treated LXRKO mice (Figure 4-
A). The induction of ChREBP expression by 
TH is thus LXR independent. TR and LXR 
activate the ChREBP promoter by respectively 
binding to LXRE2 and LXRE1 two elements 
located in the close vicinity of each other. We 
thus assayed a potential functional interaction 
between the two signalling pathways. In liver 
but not in WAT TH induction of ChREBP 
expression was significantly higher in LXRKO 
mice than in WT (4.5 fold versus 2.9 fold, 
respectively, Figure 4-A) suggesting that LXR 
might limit TR access to the promoter in WT 
liver. Such an increase is not observed for the 
regulation of other genes such as FAS which is 
known to be regulated by both pathways. To 
document this interference for promoter binding 
transfection experiments were performed in 
presence of non limiting amounts of RXR. 
Transfected alone TR or LXR induced 
pChREBP activity in the presence of their 
cognate ligands (respectively TH and T09). 
Remarkably cotransfection of both decreased 
the response to each ligand, LXR dependent 
activity being more affected than TR (Figure 
4B left panel) by this inhibition. T09 and T3 
displayed additive effects when both receptors 
were present. These observations support the 
fact that concomitant binding of the two 
receptors to a single ChREBP promoter does 
not occur. This mutual inhibition was also 
observed to a lesser extent for both TR and 
LXR activities when increasing amounts of the 
other receptor were added. (Figure 4B right 
panel). Finally direct evidences for a mutually 
exclusive binding were obtained by EMSA 
experiments. As previously shown in figure 3 
both receptors bind as RXR heterodimers to a 
44-mer probe containing the two WT LXREs. 
These two complexes migrated at different sizes 
indicated on the figure. The LXR/RXR 
complex bound to the WT probe was gradually 
displaced by increasing amount of TR/RXR 
which noticeably failed to bind the probe even 
at the highest amount added. We also observed 
that a TR/RXR complex was displaced by 
addition of LXR/RXR. However in both cases, 
the newly added complex was perfectly able to 
bind in a dose dependent manner if the probe 
used contained a mutated version of the LXRE 
required for the fixation of the initially present 
receptor (M1 for LXR and M2 for TR). 
Altogether these data strongly suggest that 
despite using two different LXREs, in this in 
vitro setting, concomitant binding of LXR/RXR 
and TR/RXR to the ChREBP promoter 
fragment is prevented. 
As a complementary way to analyze the  
interference between LXR and TR signalling 
pathways mice or WAT explants were treated 
with different combinations of LXR and TR 
ligands (Figure 4D).The efficiency of the 
different treatments was validated by measuring 
the expression levels of known LXR or TR 
targets in the two considered systems. In WAT 
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explants all genes behaved as expected with 
strong induction of ABCA1, SREBP1c and 
ApoE by T09, whereas ChREBP and FAS were 
stimulated by T3. Surprisingly in these same 
samples, LXR ligand failed to induce ChREBP 
expression. Cotreatment with both ligands did 
not yield any additional effect as compared to 
treatment with individual ligand for any of the 
target tested. This suggests that TR and LXR 
mainly possess a non overlapping set of targets 
in WAT. In liver treatments were also efficient, 
with an increase of both ChREBP and FAS by 
TR and LXR ligand alone. In this condition 
ChREBP induction by T09 does not reach 
statistical significance but lack of strong 
induction have already been described by others 
(32) 
Co-treatment with T09 and TH led to a 
significant increase in ChREBP as well as FAS 
liver expression as compared to TH treatment 
alone. This suggests that the two signals can be 
additive in this organ. For SREBP1-c and 
ABCA1 the situation is more complex. In PTU 
treated mice no activation was detected by T09 
alone and TH repressed expression of both 
genes Nonetheless T09 strongly increased their 
expression in TH-treated animals.  
Altogether these data demonstrate that TR and 
LXR are both active in the two lipogenic 
tissues, WAT and liver, although their target 
genes are different in vivo and depend on the 
tissue considered. 
 
DISCUSSION 
 
In this report we show that in mice ChREBP is 
a new direct TH target not only in liver, which 
is in agreement with recently published data 
(23), but also to a much higher extent in WAT. 
Careful dissection of the molecular mechanism 
of ChREBP regulation allowed demonstrating 
that TR, but not TR, is required for this ac-
tivity in vivo and interferes with LXR signaling. 
TH stimulate ChREBP expression in a TR 
dependent manner in liver and WAT.  
TH have been long known to regulate energy 
metabolism and lipogenesis in the liver (9-11), 
yet their lipogenic effect in other tissues such as 
WAT was still controversial. Measurement of 
in vivo hepatic lipogenesis demonstrates that 
TH induction of this process is TR-mediated 
since it was abrogated in TR-/-. Notably this 
regulation by TR correlates with its ability to 
up-regulate ChREBP expression not only in 
liver but also in WAT the second most 
important lipogenic tissue in mice. Remarkably, 
regulation of ChREBP expression is 
particularly important in WAT as compared to 
liver under acute exposure to TH. In WAT both 
TR1 and TR1 are strongly expressed. The 
lack of induction by TH of the lipogenic genes 
in TR-/- WAT clearly demonstrates that TR is 
required for the regulation of this pathway by 
TH.  The reduced, but significant, response to 
TH in TR0/0 WAT might suggest a possible 
role for TR, but is most likely due to 
variability in the amplitude of the response 
between different groups. Indeed, a similar 
variability (from 1.4 fold to 4 fold) has been 
observed within different experiments studying 
the TH-mediated ChREBP up-regulation in WT 
animals. In any case, TR but not TR is 
sufficient to drive TH induced ChREBP 
expression in WAT. High basal lipogenesis was 
observed in the PTU-treated mutant mice as 
compared to WT (SI 3). ChREBP expression is 
repressed when WT but not TR-/- mice are 
switched from a regular to a PTU diet 
suggesting that unliganded TR acts as a 
repressor of ChREBP and might thus be 
considered as lipogenesis suppressor. 
Nonetheless loss of ChREBP regulation is not 
the only explanation for higher lipogenesis in 
the TR-/-since similar ChREBP expression 
levels were found in WT under chow and TR-/- 
under different diets but were associated with 
very different levels of lipogenesis.  
Molecular determinants for the TRspecificity 
on TH-induced ChREBP expression. 
The study of the ChREBP promoter showed 
that TR specificity of the TH response in vivo 
was not mimicked in vitro, and identified the 
previously described LXRE2 as a functional 
TRE for both TR and TR.  In contrast to 
published data (23) mutation of the LXRE2 in 
the promoter did not lead to a complete loss of 
its TH inducibility. The particular mutations 
introduced in the two studies are different. 
Given the EMSA results, it is likely that for the 
present study, this mutation as well as the one 
introduced in the LXRE1 are disruptive enough 
to respectively prevent TR and LXR binding in 
in vitro setting but not in the full promoter 
environment.  
ChIP and EMSA experiments demonstrated that 
both TR and TR are bound to the LXRE2, 
excluding a specific binding for TR. Using 
KO mice Winter et al. previously characterized 
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a similar situation in some cells of the inner ear 
where prestin and KCNQ4 were specifically 
regulated by TR and TR, respectively (18). 
In this case neither ChIP nor transfection 
experiments were performed to show a direct 
regulation but both receptors bound to the two 
isolated TREs in EMSA. 
The molecular cues responsible for the TR 
versus TR specificity in vivo remain to be 
determined but altogether the results obtained 
for these three genes suggest that the 
recruitment of coregulators or the interaction 
with other transcription factors present on the 
promoter, necessary to efficiently stimulate 
transcription might indeed be isoform specific.  
Interaction of TR and LXR signallings in the 
regulation of ChREBP expression and lipid 
metabolism. 
TR and LXRs share a set of activities. Two 
hypotheses were proposed in the literature to 
document the mechanisms of these common 
functions. First LXR has been described as a 
TH target in mouse liver (20, 21). Second these 
two transcription factors can recognize and bind 
as RXR heterodimers to similar response ele-
ment in vitro, and thus might control the same 
target set. In this paper we showed that LXR 
is not regulated by TH in any of the systems 
tested (Figure 4).  Furthermore we 
demonstrated a transcriptional activation of 
ChREBP by TH and its persistance in LXRKO 
mice. Therefore the requirement of LXRs in 
this TH-controlled pathway can be excluded. 
Moreover in the liver of these LXRKO mice the 
induction of ChREBP by TH is more important 
than in WT suggesting that these receptors 
might limit each other’s access to the promoter 
at least in this tissue. The proximity of the two 
binding sites, only separated by 8 base pairs, 
respectively used by LXR and TR might impair 
the concomitant binding of the two complexes 
on a given copy of the promoter. Different ap-
proaches were adopted to test this hypothesis. 
Results from EMSA, clearly show that the two 
complexes were not observed together on a 
probe. The exclusive binding of either TR or 
LXR was only possible when the other one was 
absent or not able to bind to its mutated site. In 
addition response to T09 or TH are decreased in 
cells co-transfected with both LXR and TR as 
compared to each alone, supporting the idea 
that randomly some copy of the transfected 
promoters bind LXR, the others TR. 
In this context the additive effect of TR and 
LXR ligands on ChREBP expression in liver 
might at first appears contradictory but is likely 
to reflect the random binding of LXR or TR in 
every single cell.  
The situation is very different in the WAT. 
Strikingly and in contrast to TR, LXR does 
not regulate ChREBP in this tissue despite its 
strong induction of another of its targets, AB-
CA1. This might reflect either a lower LXR/TR 
expression ratio in this tissue and thus a prefe-
rential TR binding to the ChREBP promoter or 
a lack of LXR binding to the ChREBP promo-
ter in WAT.  
In conclusion the possible co-regulation by TRs 
and LXRs has been suggested for some time 
but while in vitro these receptors share the 
capacity to activate transcription through the 
same response elements, validation of this 
observation on natural promoters is far to be 
systematic. Indeed a number of LXR targets 
such as ABCA1, SREBP-1c and ApoE, 
containing a well recognized DR4 element, are 
unresponsive to- or decreased by TH, in WAT 
or liver respectively (figure 4). In contrast 
others such as the one in the cyp7a1 promoter 
allow the recruitment of both (21). The 
ChREBP promoter is a novel situation where 
independent binding of TR or LXR to different 
DR4 elements located close to each other will 
prevent concomitant binding of the other. One 
explanation resides in what is actually called a 
DR4 element. The direct repetition of perfect 
consensus sequences separated by 4 nucleotides 
is very rarely found in the genome. The nature 
of the actual sequence might dictate the binding 
specificity of TR versus LXR. Finally, binding 
is unlikely to be sufficient as suggested by the 
lack of TR activity despite binding on 
ChREBP promoter in WAT and the different 
mode of regulation for a given receptor on a 
given promoter in two different tissues. 
Importance of ChREBP induction in the TH 
induced expression of lipogenic genes. 
Another question is the importance of ChREBP 
activation during TH-induced lipogenesis. 
Clearly in both lipogenic tissues tested 
ChREBP regulation is concomitant with the 
induction of the genes encoding the enzymes of 
the lipogenesis pathway. We do not have any 
direct evidence that ChREBP is actually re-
quired for the regulation of these genes that all 
contain a ChoRE. This is likely the case for 
genes, such as FAS or SCD1, in which no con-
sensus TRE was ever found. For other genes, 
TR and LXR regulate ChREBP in a tissue selective manner 
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such as ME and Spot14, with characterized 
TRE, ChREBP and TR might act in an 
additive manner. Similar co-regulation of genes 
involved in the lipogenic pathways have been 
suggested for LXR and ChREBP.  
Physiological relevance of TH induced tran-
scriptional regulation of ChREBP. 
In the liver the ChREBP protein is always high-
ly expressed, the regulation of ChREBP mRNA 
expression is thus generally not considered as a 
major parameter for modulating its activity 
which mainly relies on rapid post-translational 
modifications (5). In contrast, the ChREBP 
transcript level is lower in WAT and as we 
show here highly inducible by both TH and 
refeeding. Although lipogenesis per se was not 
measured, both stimuli induce the expression of 
lipogenic genes (FAS, SPOT14) suggesting that 
in WAT, activated ChREBP drives the same 
response as in liver. Under these conditions 
WAT might thus contribute to the increase of 
whole body lipogenesis in a significant manner. 
It is also important to note that exogenous TH 
can modulate the expression of ChREBP and 
other lipogenic under non lipogenic condition 
such as fasting, supporting the hypothesis that 
nutritional status and TH are two independent 
ways to induce ChREBP levels at least in 
WAT. 
In agreement with the absence of ChREBP up 
regulation by T09 in WAT, and with data 
published by others (6), ChREBP response to 
refeeding is also maintained in LXRKO mice 
(SI4). Other factor than TR or LXR must then 
be responsible for this physiological increase of 
ChREBP expression. 
Refeeding drives blood insulin level to rise. 
This hormone is thus likely to be responsible 
for the strong regulation of ChREBP in WAT, 
as shown in 3T3L1 adipocytes (8). Circulating 
TH levels decrease (around 50% for both T3 
and T4) during short term starvation (33) and 
take several days to return normal. This 
variation of TH circulating levels is unlikely to 
be sufficient to amplify the stimulation of 
refeeding on ChREBP expression since TH 
injection in those conditions failed to do so and 
TR signalling was not necessary to this 
induction. Our hypothesis is that in other 
physiological situations associated with a 
modification of either local or circulating 
concentrations of TH, ChREBP would 
accumulate.  
This work opens new perspectives since turning 
TR into a repressor in certain metabolic 
tissues, using a TR specific ligand yet to be 
developed could be one way to inhibit ChREBP 
expression and therefore lipogenesis induced by 
carbohydrate consumption. This could help 
improving patients with hepatic steatosis and 
insulin-resistance (34). 
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FIGURE LEGENDS 
 
Figure 1 ChREBP expression and lipogenesis are regulated by thyroid hormones in a TR dependent 
manner. 3-month old males either genetically (pax8
-/-
) or chemically rendered (WT, TR-/-, TR0/0 -
PTU treated) hypothyroid were either injected by PBS (white bars) or TH (black bars). In A) (n=4 for 
higher panel, n=5 for lower panel) and B) (n=5) mRNA encoding lipogenic enzymes were quantified 
by QRTPCR. In C) liver lipogenesis was measured as described in Material and methods (n=5). 
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Results are shown as induction as compared to the PTU treated animals of a given genotype. Stars and 
dollar signs indicate respectively statistical significance as compared to the PTU treatment of the same 
genotype and to the equivalent treatment in the WT group (
$ or* p≤0.05, $$ or ** p≤0.005, $$$ or 
***p≤0.0005). 
Figure 2 Independent regulation of ChREBP expression by TH/TR and nutritional status.WT and 
TR-/- 3-month old male mice were submitted to modification of nutritional and/or TH status. In A) 
mice were either fed a regular chow diet (CF), or starved for 24h and then refed (R) or not (F). (n=5). 
In B) mice were starved for 24h. One group was kept on fasting (F), the other one was refed (R) for an 
additional 16h. Half of the animals per group were injected by TH twice, one before the fast then 
before the refeeding (n=5). Expression of lipogenic genes was measured by QRTPCR. Stars indicate 
statistical significance (* p≤0.05, ** p≤0.005, ***p≤0.0005) as compared to the CF group of the same 
genotype in A), to the F/V group in B). $ indicate statistical significance between F and RF groups in 
A) and bridged groups in B) ($ p≤0.05, $$ p≤0.005, $$$ p≤0.0005). In A) the value for the relative 
expression has been fixed to one in each genotype for the CF group. 
Figure 3 TR and TRbind to and activate ChREBP promoter via the previously described 
LXRE2.Scheme of the different versions of the ChREBP promoter cloned upstream of a luciferase 
reporter. LXRE1 and LXRE2 are pictured as black ovals or white when mutated. The top arrow 
materializes the transcription start site. The arrows pairs below the promoter indicate the localization 
of the primers used for ChIP analyzes: white for NS2, black for S1, and grey for NS1. The region 
amplified by these three pairs are respectively the promoter portion -4100/-3900, -2558/-2384 and -
203/+4. B) The indicated promoters were transfected with either TR,TR or LXR together with an 
RXR encoding plasmid and treated with either vehicle (white), T3 (light grey) or T09 (dark grey). 
The relative luciferase activity measured is reported as arbitrary units (RAU). C) EMSA were 
performed using a 44 bp long probe from the ChREBP promoter (WT probe) containing the area with 
the two LXREs, to detect TR/RXR or TR/RXR binding. LXR/RXR has been included as a 
control. Competition with 100 fold excess of cold smaller fragments containing only one of the two 
LXREs either wt (LXRE1 or LXRE2) or mutated (LXRE1mut or LXRE2mut) were used to assess the 
specificity of the binding. D) ChIP experiments were performed on differentiated 3T3L1, treated 
(black) or not (light grey) with T3. On the left are results obtained with anti-TRTR), anti-
TRTR or mouse IgG (IgG), on the right those obtained with anti-RNApolII (RPII) and mouse 
IgG (IgG). Specificity of the antibodies used was verified on transfected Hela cells (SI2).The same 
lysates were used for all conditions and each precipitation was done in replicates. The results shown 
are an average of these duplicates. Each experiment has been repeated at least twice. The primers pairs 
used for detection are indicated under the arrows.  
Figure 4 Interactions between LXR and TR signalling. A) 9-month old WT or LXRKO females were 
rendered hypothyroid by PTU treatment and either injected by PBS (white bars) or TH (black bars) 
(n=5) (left panel). Fat pads isolated from either WT or LXRDKO were kept in culture for two days in 
presence of the indicated ligands for the last 24h (right panel). 
B) The pChREBP construct (see figure 3) was transfected together with high amount (150ng) of 
RXR and the indicated combination of TR and LXR (50ng each) (left panel) or an increasing 
amount (50, 100 and 200ng) of either TR1 or LXR (right panel) depicted as the black triangle. Cells 
were then treated with either vehicle (white), T3 (light grey), T09 (dark grey) or a combination of both 
(black). The relative luciferase activity measured is reported as arbitrary units (RAU). C) EMSA were 
performed to assess competition between LXR and TR for binding to the promoter using either a WT 
(as described in figure 3), a M1 (WT LXRE2, mutated LXRE1) or a M2 (WT LXRE1, mutated 
LXRE2) probe (Indicated at the bottom of the gels). A fix amount of LXR/RXR (two left panels) or 
TR1/RXR (two right panels) complex was incubated with increasing amount of the other complex 
respectively TR1/RXR and LXR/RXR (x2, x4, x8 materialised by the black triangle). The two 
different complexes migrate at different size indicated by the arrows. D) 3-month old WT males were 
rendered hypothyroid by PTU treatment and either injected by PBS or TH. For each group, half of the 
animals were treated with T09 or vehicle) (left panel) Fat pads isolated from WT mice were kept in 
culture for two days in presence of the indicated ligands for the last 24h (right panel).  (n=5). For A) 
and D) QRTPCR analyses were performed on liver and fad pads For the four panels stars or dollars 
indicate statistical significance (one p≤0.05, two p≤0.005, three p≤0.0005). Stars are always for 
TR and LXR regulate ChREBP in a tissue selective manner 
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significance between the given and control group for a genotype (PBS in A, and veh in D), dollars for 
the significance between the bridged groups. 
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